

- 3 Please complete the table below with how many **newly diagnosed** patients with CLL have **started first-line treatment** with each of the following CITs during the 6-month period February 2024 to July 2024
- FCR (fludarabine + cyclophosphamide + rituximab)
 - FR (fludarabine + rituximab)
 - BR (bendamustine + rituximab)
 - Bendamustine monotherapy
 - RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
 - Obinutuzumab ± chlorambucil
 - Rituximab + chlorambucil
 - Ofatumumab
 - Other - please specify

Note: this should only include **newly diagnosed** patients with CLL who have **started first-line treatment during the 6-month window**

Answer:

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	<i>Zero</i>
FR	<i>Zero</i>
BR	<i>Zero</i>
Bendamustine monotherapy	<i>Zero</i>
R-CHOP	<i>Zero</i>
Obinutuzumab ± chlorambucil	<i>Zero</i>
Rituximab + chlorambucil	<i>Zero</i>
Chlorambucil monotherapy	<i>Zero</i>
Rituximab monotherapy	<i>Zero</i>
Ofatumumab	<i>Zero</i>
Other - please specify	<i>>5 received first line Obinutuzumab + venetoclax</i>